GlassScriptPhysician profile
Greta L Laube
NPI 1821057423
$5,863.21
in general payments reported to CMS, 2019-2025
26 companies · $758 in 2025
The $758 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $720 · 2021: $942 · 2022: $1,034 · 2023: $805 · 2024: $787 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.56 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,255.21 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $546.52 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Ironshore Pharmaceuticals INC. | $506.39 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $497.27 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Pfizer INC. | $439.64 | 2019-2025 | |
| Corium, LLC | $420.42 | 2022-2025 | Azstarys, Azstarys |
| Neos Therapeutics, LP | $366.57 | 2019-2023 | Cotempla Xr-Odt |
| Kaleo, INC. | $231.80 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $217.17 | 2019-2025 | Quillivant |
| Astrazeneca Pharmaceuticals LP | $188.31 | 2019-2020 | |
| Adlon Therapeutics L.P. | $178.16 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $176.68 | 2023-2024 | |
| Sanofi Pasteur INC. | $161.09 | 2021-2025 | |
| Sobi, INC | $124.73 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $115.36 | 2025 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $94.46 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $73.25 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $60.24 | 2024-2025 | Relexxii |
| Biogen, INC. | $44.41 | 2023-2025 | Spinraza |
| Genentech USA, INC. | $40.84 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $32.48 | 2021 | |
| Aimmune Therapeutics, INC. | $22.33 | 2021 | |
| Shire North American Group INC | $19.43 | 2019 | |
| Seqirus USA INC | $19.31 | 2025 | Flucelvax |
| Verrica Pharmaceuticals INC. | $16.46 | 2024 | Ycanth |
| Hologic Sales and Service, LLC | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greta Laube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.